Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark

• Published in: Expert review of vaccines Vol. 20; no. 10; pp. 1327 - 1337
• Main Authors: Birck, Anders Muusfeldt, Nordin Christensen, Liv, Pedersen, Mikkel H., Olsen, Jens, Johnson, Kelly D., Bencina, Goran, Clausen, Thomas Holtkøtter, Larsen, Carsten Schade
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03.10.2021
• Subjects: Adult; Aged; Cost-Benefit Analysis; cost-effectiveness; Costs; Denmark - epidemiology; Humans; Middle Aged; pneumococcal disease; Pneumococcal Infections - epidemiology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines; Pneumonia, Pneumococcal - epidemiology; Pneumonia, Pneumococcal - prevention & control; PPSV23; Vaccination; vaccination programme; vaccine; Denmark; cost-effectiveness; Costs; vaccine; PPSV23; pneumococcal disease; vaccination programme
• ISSN: 1476-0584; 1744-8395
• DOI: 10.1080/14760584.2021.1977627

To estimate the health economic consequences of the recently introduced PPSV23 vaccination programme for persons aged 65+ in Denmark and of a potential extension of the programme to include persons aged 60-64 years. A Markov model was adapted to the Danish healthcare setting to simulate the epidemiological and economic burden of invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia using information from published sources and Danish databases. We found that the recent introduction of an age-based vaccination programme offering PPSV23 vaccination to the population of persons aged 65+ in Denmark will lead to a societal gain of EUR 72.0 million and prevent 19,707 cases of pneumococcal disease and 1,308 deaths per 1 million persons during the five-year study period. Similarly, we estimate that extending the programme to include persons aged 60-64 will lead to a gain of EUR 14.6 million per 1 million persons and prevent an additional 6,223 cases of pneumococcal disease and 185 deaths. The recent introduction of the age-based vaccination programme offering PPSV23 vaccination to all persons aged 65+ in Denmark is cost-effective. This is also the case if the programme is extended to include persons aged 60-64.